LyncBio Therapeutics
Latest round
- Series A
Last raised
- May 2026
Total raised
- Undisclosed
Investors
- 5
About LyncBio Therapeutics
, dba LyncBio Therapeutics, is a biotechnology company specializing in developing innovative Antibody-Drug Conjugates (ADCs) aimed at improving targeted cancer therapies. LyncBio Therapeutics specializes in the development and innovation of next-generation Antibody-Drug Conjugates (ADCs), designed to enhance targeted cancer therapies. Their offerings include a suite of multifunctional carriers, conjugates, linkers, and drug payloads, enabling precise targeting of cancer cells via single-target and dual-target ADC designs. The company utilizes advanced methodologies and proprietary technology platforms to address global patient needs in oncology, inflammatory bowel disease, and multiple sclerosis, aiming for broad international market reach. LyncBio generates revenue through strategic partnerships and collaborations with healthcare providers and research institutions seeking advanced therapeutic solutions.
Who invested in LyncBio Therapeutics
5 investors across 3 rounds
See all investors in LyncBio Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about LyncBio Therapeutics
Who invested in LyncBio Therapeutics?
LyncBio Therapeutics has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has LyncBio Therapeutics raised?
LyncBio Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did LyncBio Therapeutics last raise money?
LyncBio Therapeutics's most recent round on record is a Series A, in May 2026.
What does LyncBio Therapeutics do?
, dba LyncBio Therapeutics, is a biotechnology company specializing in developing innovative Antibody-Drug Conjugates (ADCs) aimed at improving targeted cancer therapies.
Where is LyncBio Therapeutics headquartered?
LyncBio Therapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like LyncBio Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at LyncBio Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like LyncBio Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.